5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 15.46▼ | 15.23▲ | 15.19▲ | 14.54▲ | 14.17▲ |
MA10 | 15.36▲ | 15.17▲ | 15.14▲ | 14.34▲ | 13.30▲ |
MA20 | 15.30▲ | 15.15▲ | 15.18▲ | 14.15▲ | 11.63▲ |
MA50 | 15.19▲ | 14.73▲ | 14.18▲ | 13.35▲ | N/A |
MA100 | 15.18▲ | 14.20▲ | 14.13▲ | 11.67▲ | N/A |
MA200 | 14.65▲ | 14.12▲ | 14.23▲ | 14.46▲ | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.017▲ | -0.011▼ | -0.030▼ | 0.065▲ | 0.895▲ |
RSI | 55.714▲ | 60.639▲ | 64.238▲ | 60.108▲ | 57.146▲ |
STOCH | 74.749 | 59.836 | 59.510 | 47.543 | 72.367 |
WILL %R | -62.791 | -34.177 | -34.177 | -18.387▲ | -8.108▲ |
CCI | 53.108 | 180.912▲ | 208.743▲ | 121.126▲ | 101.226▲ |
Friday, August 15, 2025 07:33 AM
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at ...
|
Monday, August 11, 2025 01:16 PM
A Phase 2a trial of ORKA-001, with data expected in 2H 2026 ORKA-001 Phase 1 data and EVERLAST-A design to be presented at EADV in September 2025 ORKA-002 Phase 1 trial ongoing, with data to be ...
|
Monday, July 21, 2025 04:59 AM
News provided by Oruka Therapeutics, Inc. Jul 21, 2025, 7:00 AM ET IND cleared for the EVERLAST-A Phase 2a trial of ORKA-001 in moderate-to-severe psoriasis, with initial data expected 2H 2026 ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
15/08/25 | 15.06 | 15.67 | 14.79 | 15.37 | 155,900 |
14/08/25 | 15.03 | 15.41 | 14.85 | 15.00 | 123,700 |
13/08/25 | 14.03 | 15.94 | 14.03 | 15.33 | 303,600 |
12/08/25 | 13.22 | 14.21 | 13.06 | 13.95 | 210,122 |
11/08/25 | 13.17 | 13.58 | 12.84 | 13.05 | 101,100 |
08/08/25 | 13.80 | 13.90 | 12.89 | 13.09 | 71,500 |
07/08/25 | 14.20 | 14.54 | 13.49 | 13.67 | 113,900 |
06/08/25 | 15.51 | 15.68 | 13.86 | 14.19 | 171,200 |
05/08/25 | 14.31 | 15.52 | 14.17 | 15.50 | 202,600 |
04/08/25 | 13.75 | 14.45 | 13.52 | 14.30 | 93,300 |
|
|
||||
|
|
||||
|
|